Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: J Leukoc Biol. 2019 Jan 28;105(4):729–740. doi: 10.1002/JLB.3A0818-329RRR

Figure 7. PAR inhibitors block plasmin-induced pro-inflammatory cytokine expression.

Figure 7.

(A) BMDMs were treated with 12 nM enzymatically-active tPA (EA-tPA) plus 200 nM plasminogen (Plg), EA-tPA alone, or Plg alone, in the presence or absence of SCH-79797 (SCH) (2 μM) as indicated for 3 h. (B) BMDMs were pre-treated with RWJ-56110 (RWJ) (30 μM) or vehicle for 2 h and then with EA-tPA (12 nM) plus Plg (200 nM), LPS (0.1 μg/ml), or vehicle for 3 h. RT-qPCR was performed to compare mRNA levels for TNFα, IL-1β, IL-6 and CCL2 (mean ± SEM; n = 3–4; **p<0.01, ***p<0.001, N.S., not statistically significant; one-way ANOVA with Bonferroni’s post hoc analysis). The presented results show “fold increase” in mRNA expression compared with cultures treated with vehicle.